Grown Rogue International (GRUSF) EBT Margin (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly EBT Margin came in at 18.53% in Q1 2026, down 3775.0% year-on-year from 0.5% in Q1 2025, and down 151.69% quarter-over-quarter from 35.85% in Q4 2025.
Grown Rogue International (GRUSF) EBT Margin (2009 - 2026) Analysis & Trends
Grown Rogue International's EBT Margin history runs 16 years deep, the most recent figure standing at 18.53% for Q1 2026.
- On a quarterly basis, EBT Margin fell 3775.0% year-over-year to 18.53% in Q1 2026; TTM through Mar 2026 was 53.84%, a 2428403959.0% decrease from a year earlier, with the FY2025 full-year figure at 1.58%, down 430.0% from the prior year.
- EBT Margin eased to 18.53% in Q1 2026 per GRUSF's latest filing, from 35.85% in the prior quarter.
- Across five years, EBT Margin topped out at 42163425.45% in Q4 2024 and bottomed at 7966355.51% in Q3 2024.
- The 5-year median for EBT Margin is 5.16% (2022), against an average of 2279801.88%.
- Across the five-year window, EBT Margin jumped 2000000000 bps in 2024 and slumped 2000000000 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 5.16% in 2022, then tumbled by 458 bps to 18.48% in 2023, then jumped by 228120342 bps to 42163425.45% in 2024, then plunged by 100 bps to 35.85% in 2025, then plunged by 152 bps to 18.53% in 2026.
- Per Business Quant, the three latest GRUSF EBT Margin figures stand at 18.53% (Q1 2026), 35.85% (Q4 2025), and 54.29% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | -18.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.53% |
| Dec 31, 2025 | 35.85% |
| Sep 30, 2025 | 54.29% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 19.22% |
| Dec 31, 2024 | 42,163,425.45% |
| Sep 30, 2024 | -7,966,355.51% |
| Jun 30, 2024 | -90.97% |
| Mar 31, 2024 | -57.03% |
| Dec 31, 2023 | -18.48% |
| Oct 31, 2023 | -5.09% |
| Jul 31, 2023 | 8.60% |
| Apr 30, 2023 | 10.52% |
| Jan 31, 2023 | 14.73% |
| Jan 31, 2022 | 5.16% |
| Oct 31, 2021 | 43.06% |
| Jul 31, 2021 | 25.23% |
| Apr 30, 2021 | -38.13% |
| Jan 31, 2021 | -94.71% |
| Oct 31, 2020 | -336.38% |